🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the effort against increasingly resistant strains of the infection, according to researchers.

A Global Challenge

Gonorrhoea infections are increasing worldwide, with data suggesting more than 82 million new cases each year. Especially elevated rates are reported in the African continent and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely advancement in the context of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The global health body has classified it as a "critical concern". Ongoing monitoring found that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, also known as Nuzolvence, was authorized by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This drug, which is employed against UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a unique collaborative effort for medication research. The charitable organization GARDP collaborated with the drug firm Innoviva to see it through.

“This approval represents a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Results and Global Access

Based on results published in a prominent scientific publication, the new drug cured more than 90% of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which uses an injection and a pill. The study enrolled hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the ability to register and commercialise the drug in many developing nations.

Doctors treating patients have expressed positive views. Access to a single-dose, oral treatment like this is seen as a "revolutionary step" for managing the epidemic. This is considered essential to lessen the impact of the disease for people and to halt the transmission of highly drug-resistant gonorrhoea globally.